Health-Related Quality of Life and Satisfaction With Health Care

Relation to Clinical Stage in Mexican Patients With Multiple Myeloma

Luz Ma Adriana Balderas-Peña, Claudia Miranda-Ruvalcaba, Andrea Isabel Robles-Espinoza, Daniel Sat-Muñoz, Miguel Garcés Ruiz, Eduardo García-Luna, Arnulfo Hernan Nava-Zavala, Benjamín Rubio-Jurado

Research output: Contribution to journalArticle

Abstract

Multiple myeloma (MM) is characterized by bone pain, pathologic fractures, bone destruction, and secondary hypercalcemia, all these conditions impact on health-related quality of life of patients. The objective was to evaluate the global health state and health-related quality of life in a group of patients with MM who attended a tertiary health-care center of the Instituto Mexicano del Seguro Social in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality of life group. Exploratory cross-sectional study in patients with MM treated in a Department of Hematology in a High-Specialty Medical Unit was conducted. Patients older than 18 years of age, men and women, were selected, and their informed written consent was obtained. We included all consecutive cases treated from January 2012 to December 2014. Questionnaires EORTC QLQ-C30, EORTC QLQ-MY20, and EORTC IN-PATSAT-32 were used. We studied 37 patients, 19 (51%) men and 18 women. The mean age was 61.9 years. Twenty-two (59.46%) patients presented with clinical stage III. The mean time for diagnosis was 33.11 months. The most used first-line treatment schedule was melphalan/prednisone/thalidomide (15; 40%). The global health median was 66.67, and symptoms showed a median score of 22.22. Treatment side effects score was 16.67; for general satisfaction, the median score was 75. In conclusion, the patients showed an advanced clinical stage and poor prognosis but had scores higher than 50 in functional scales and lower than 50 for symptom scales. The scores for symptom scales were related to age, renal failure, and disease-free survival. Identification of quality of life and satisfaction of care markers allow for early therapeutic intervention and efficiency and enable a change in quality of life and perception of care in Health Services.

Original languageEnglish
Number of pages8
JournalCancer Control
Volume26
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Multiple Myeloma
Quality of Life
Delivery of Health Care
Organizations
Research
Therapeutics
Neoplasms
Bone and Bones
Spontaneous Fractures
Melphalan
Thalidomide
Hypercalcemia
Hematology
Prednisone
Mexico
Informed Consent
Tertiary Care Centers
Disease-Free Survival
Health Services
Renal Insufficiency

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Balderas-Peña, Luz Ma Adriana ; Miranda-Ruvalcaba, Claudia ; Robles-Espinoza, Andrea Isabel ; Sat-Muñoz, Daniel ; Ruiz, Miguel Garcés ; García-Luna, Eduardo ; Nava-Zavala, Arnulfo Hernan ; Rubio-Jurado, Benjamín. / Health-Related Quality of Life and Satisfaction With Health Care : Relation to Clinical Stage in Mexican Patients With Multiple Myeloma. In: Cancer Control. 2019 ; Vol. 26, No. 1.
@article{55d62ad339a6481f969809dff71bf773,
title = "Health-Related Quality of Life and Satisfaction With Health Care: Relation to Clinical Stage in Mexican Patients With Multiple Myeloma",
abstract = "Multiple myeloma (MM) is characterized by bone pain, pathologic fractures, bone destruction, and secondary hypercalcemia, all these conditions impact on health-related quality of life of patients. The objective was to evaluate the global health state and health-related quality of life in a group of patients with MM who attended a tertiary health-care center of the Instituto Mexicano del Seguro Social in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality of life group. Exploratory cross-sectional study in patients with MM treated in a Department of Hematology in a High-Specialty Medical Unit was conducted. Patients older than 18 years of age, men and women, were selected, and their informed written consent was obtained. We included all consecutive cases treated from January 2012 to December 2014. Questionnaires EORTC QLQ-C30, EORTC QLQ-MY20, and EORTC IN-PATSAT-32 were used. We studied 37 patients, 19 (51{\%}) men and 18 women. The mean age was 61.9 years. Twenty-two (59.46{\%}) patients presented with clinical stage III. The mean time for diagnosis was 33.11 months. The most used first-line treatment schedule was melphalan/prednisone/thalidomide (15; 40{\%}). The global health median was 66.67, and symptoms showed a median score of 22.22. Treatment side effects score was 16.67; for general satisfaction, the median score was 75. In conclusion, the patients showed an advanced clinical stage and poor prognosis but had scores higher than 50 in functional scales and lower than 50 for symptom scales. The scores for symptom scales were related to age, renal failure, and disease-free survival. Identification of quality of life and satisfaction of care markers allow for early therapeutic intervention and efficiency and enable a change in quality of life and perception of care in Health Services.",
author = "Balderas-Pe{\~n}a, {Luz Ma Adriana} and Claudia Miranda-Ruvalcaba and Robles-Espinoza, {Andrea Isabel} and Daniel Sat-Mu{\~n}oz and Ruiz, {Miguel Garc{\'e}s} and Eduardo Garc{\'i}a-Luna and Nava-Zavala, {Arnulfo Hernan} and Benjam{\'i}n Rubio-Jurado",
year = "2019",
month = "1",
day = "1",
doi = "10.1177/1073274819831281",
language = "English",
volume = "26",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "1",

}

Health-Related Quality of Life and Satisfaction With Health Care : Relation to Clinical Stage in Mexican Patients With Multiple Myeloma. / Balderas-Peña, Luz Ma Adriana; Miranda-Ruvalcaba, Claudia; Robles-Espinoza, Andrea Isabel; Sat-Muñoz, Daniel; Ruiz, Miguel Garcés; García-Luna, Eduardo; Nava-Zavala, Arnulfo Hernan; Rubio-Jurado, Benjamín.

In: Cancer Control, Vol. 26, No. 1, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Health-Related Quality of Life and Satisfaction With Health Care

T2 - Relation to Clinical Stage in Mexican Patients With Multiple Myeloma

AU - Balderas-Peña, Luz Ma Adriana

AU - Miranda-Ruvalcaba, Claudia

AU - Robles-Espinoza, Andrea Isabel

AU - Sat-Muñoz, Daniel

AU - Ruiz, Miguel Garcés

AU - García-Luna, Eduardo

AU - Nava-Zavala, Arnulfo Hernan

AU - Rubio-Jurado, Benjamín

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Multiple myeloma (MM) is characterized by bone pain, pathologic fractures, bone destruction, and secondary hypercalcemia, all these conditions impact on health-related quality of life of patients. The objective was to evaluate the global health state and health-related quality of life in a group of patients with MM who attended a tertiary health-care center of the Instituto Mexicano del Seguro Social in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality of life group. Exploratory cross-sectional study in patients with MM treated in a Department of Hematology in a High-Specialty Medical Unit was conducted. Patients older than 18 years of age, men and women, were selected, and their informed written consent was obtained. We included all consecutive cases treated from January 2012 to December 2014. Questionnaires EORTC QLQ-C30, EORTC QLQ-MY20, and EORTC IN-PATSAT-32 were used. We studied 37 patients, 19 (51%) men and 18 women. The mean age was 61.9 years. Twenty-two (59.46%) patients presented with clinical stage III. The mean time for diagnosis was 33.11 months. The most used first-line treatment schedule was melphalan/prednisone/thalidomide (15; 40%). The global health median was 66.67, and symptoms showed a median score of 22.22. Treatment side effects score was 16.67; for general satisfaction, the median score was 75. In conclusion, the patients showed an advanced clinical stage and poor prognosis but had scores higher than 50 in functional scales and lower than 50 for symptom scales. The scores for symptom scales were related to age, renal failure, and disease-free survival. Identification of quality of life and satisfaction of care markers allow for early therapeutic intervention and efficiency and enable a change in quality of life and perception of care in Health Services.

AB - Multiple myeloma (MM) is characterized by bone pain, pathologic fractures, bone destruction, and secondary hypercalcemia, all these conditions impact on health-related quality of life of patients. The objective was to evaluate the global health state and health-related quality of life in a group of patients with MM who attended a tertiary health-care center of the Instituto Mexicano del Seguro Social in Mexico, through the questionnaires designed by European Organization for Research and Treatment of Cancer (EORTC) quality of life group. Exploratory cross-sectional study in patients with MM treated in a Department of Hematology in a High-Specialty Medical Unit was conducted. Patients older than 18 years of age, men and women, were selected, and their informed written consent was obtained. We included all consecutive cases treated from January 2012 to December 2014. Questionnaires EORTC QLQ-C30, EORTC QLQ-MY20, and EORTC IN-PATSAT-32 were used. We studied 37 patients, 19 (51%) men and 18 women. The mean age was 61.9 years. Twenty-two (59.46%) patients presented with clinical stage III. The mean time for diagnosis was 33.11 months. The most used first-line treatment schedule was melphalan/prednisone/thalidomide (15; 40%). The global health median was 66.67, and symptoms showed a median score of 22.22. Treatment side effects score was 16.67; for general satisfaction, the median score was 75. In conclusion, the patients showed an advanced clinical stage and poor prognosis but had scores higher than 50 in functional scales and lower than 50 for symptom scales. The scores for symptom scales were related to age, renal failure, and disease-free survival. Identification of quality of life and satisfaction of care markers allow for early therapeutic intervention and efficiency and enable a change in quality of life and perception of care in Health Services.

UR - http://www.scopus.com/inward/record.url?scp=85061971709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061971709&partnerID=8YFLogxK

U2 - 10.1177/1073274819831281

DO - 10.1177/1073274819831281

M3 - Article

VL - 26

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 1

ER -